Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Goldman Sachs analyst Paul Choi downgraded the stock from "Neutral" to "Sell," setting a price target of $12, which is ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

PHRMAG represents 29 leading global biopharmaceutical research companies in the region. Dedicated to advancing innovation and ...

SEOUL: South Korea's acting President Choi Sang-mok (pic) on Wednesday (Feb 12) said he hoped for a swift agreement within ...

LB Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

We recently compiled a list of the 10 Mid-Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Nuvalent, Inc.